Effect of glycemic control on microalbuminuria development among type 2 diabetes with high-normal albuminuria

References

• Prevention CfDCa. National diabetes fact sheet: national estimates and general information on diabetes and prediabetes in the United States, 2011. Atlanta, GA: U.S; 2011
   Google Scholar
• Huang YY, Lin KD, Jiang YD, et al. Diabetes-related kidney, eye, and foot disease in Taiwan: an analysis of the nationwide data for 2000–2009. J Formos Med Assoc. 2012;111(11):637–644
   Google Scholar
• Yang WC, Hwang SJ, Chiang SS, Chen HF, Tsai ST. The impact of diabetes on economic costs in dialysis patients: experiences in Taiwan. Diabetes Res Clin Pract. 2001;54(Suppl 1):S47–S54
   Google Scholar
• Nichols GA, Vupputuri S, Lau H. Medical care costs associated with progression of diabetic nephropathy. Diabetes Care. 2011;34(11):2374–2378
   PubMed Web of Science ®Google Scholar
• Mogensen CE, Christensen CK, Vittinghus E. The stages in diabetic renal disease. With emphasis on the stage of incipient diabetic nephropathy. Diabetes. 1983;32(Suppl 2):64–78
   PubMed Web of Science ®Google Scholar
• Nelson RG, Bennett PH, Beck GJ, et al. Development and progression of renal disease in Pima Indians with non-insulin-dependent diabetes mellitus. Diabetic Renal Disease Study Group. N Engl J Med. 1996;335(22):1636–1642
   PubMedGoogle Scholar
• Rachmani R, Levi Z, Lidar M, et al. Considerations about the threshold value of microalbuminuria in patients with diabetes mellitus: lessons from an 8-year follow-up study of 599 patients. Diabetes Res Clin Pract. 2000;49(2–3):187–194
   Google Scholar
• Murussi M, Baglio P, Gross JL, Silveiro SP. Risk factors for microalbuminuria and macroalbuminuria in type 2 diabetic patients: a 9-year follow-up study. Diabetes Care. 2002;25(6):1101–1103
   Google Scholar
• Murussi M, Campagnolo N, Beck MO, Gross JL, Silveiro SP. High-normal levels of albuminuria predict the development of micro- and macroalbuminuria and increased mortality in Brazilian Type 2 diabetic patients: an 8-year follow-up study. Diabet Med. 2007;24(10):1136–1142
   Google Scholar
• Adler AI, Stevens RJ, Manley SE, et al. Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64). Kidney Int. 2003;63(1):225–232
   PubMed Web of Science ®Google Scholar
• Hsu CC, Chang HY, Huang MC, et al. HbA1c variability is associated with microalbuminuria development in type 2 diabetes: a 7-year prospective cohort study. Diabetologia. 2012;55(12):3163–3172
   Google Scholar
• Hsu CC, Chang HY, Huang MC, et al. Association between insulin resistance and development of microalbuminuria in type 2 diabetes: a prospective cohort study. Diabetes Care. 2011;34(4):982–987
   Google Scholar
• American Diabetes A. Standards of medical care in diabetes. Diabetes Care. 2004;27(Suppl 1):S15–35
   Google Scholar
• John L, Rao PS, Kanagasabapathy AS. Rate of progression of albuminuria in type II diabetes. Five-year prospective study from south India. Diabetes Care. 1994;17(8):888–890
   Google Scholar
• Gall MA, Hougaard P, Borch-Johnsen K, Parving HH. Risk factors for development of incipient and overt diabetic nephropathy in patients with non-insulin dependent diabetes mellitus: prospective, observational study. BMJ. 1997;314(7083):783–788
   PubMed Web of Science ®Google Scholar
• Forsblom CM, Groop PH, Ekstrand A, et al. Predictors of progression from normoalbuminuria to microalbuminuria in NIDDM. Diabetes Care. 1998;21(11):1932–1938
   Google Scholar
• Forman JP, Brenner BM. ‘Hypertension' and ‘microalbuminuria': the bell tolls for thee. Kidney Int. 2006;69(1):22–28
   Google Scholar
• Wachtell K, Ibsen H, Olsen MH, et al. Albuminuria and cardiovascular risk in hypertensive patients with left ventricular hypertrophy: the LIFE study. Ann Intern Med. 2003;139(11):901–906
   PubMed Web of Science ®Google Scholar
• Gerstein HC, Mann JF, Yi Q, et al. Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. JAMA. 2001;286(4):421–426
   PubMed Web of Science ®Google Scholar
• Ruggenenti P, Fassi A, Ilieva AP, et al. Preventing microalbuminuria in type 2 diabetes. N Engl J Med. 2004;351(19):1941–1951
   PubMed Web of Science ®Google Scholar
• Ruggenenti P, Remuzzi G. Time to abandon microalbuminuria? Kidney Int. 2006;70(7):1214–1222
   PubMedGoogle Scholar
• Stratton IM, Adler AI, Neil HA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ. 2000;321(7258):405–412
   PubMed Web of Science ®Google Scholar
• , Action to Control Cardiovascular Risk in Diabetes Study GroupGerstein HC, Miller ME, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008;358(24):2545–2559
   PubMed Web of Science ®Google Scholar
• Group AC, Patel A, MacMahon S, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008;358(24):2560–2572
   PubMed Web of Science ®Google Scholar
• Jun M, Perkovic V, Cass A. Intensive glycemic control and renal outcome. Contrib Nephrol. 2011;170:196–208
   Google Scholar
• Bilous R, Chaturvedi N, Sjolie AK, et al. Effect of candesartan on microalbuminuria and albumin excretion rate in diabetes: three randomized trials. Ann Intern Med. 2009;151(1):11–20, W13–14
   Google Scholar
• Haller H, Ito S, Izzo JL Jr, et al. Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes. N Engl J Med. 2011;364(10):907–917
   PubMed Web of Science ®Google Scholar